Latest News

A new, highly sensitive test for a cancer biomarker could allow more lung cancer patients to benefit from a recently FDA-approved chemotherapy.

Two genes could serve as a screening mechanism for resistance to immunotherapy in non-small cell lung cancer (NSCLC), though further research is needed.

A recent study conducted by scientists at Yale Cancer Center demonstrates that spatial gene signatures can significantly enhance the prediction of immunotherapy outcomes in patients with melanoma.

David Rimm, MD, PhD, Anthony N. Brady Professor of Pathology, professor, medicine, Medical Oncology, Yale School of Medicine; director, Physician Scientist Training Program, Pathology Research, director, Tissue Microarray Facility, director, Yale Pathology Tissue Services, Pathology, Yale Cancer Center, discusses the primary challenges in distinguishing between HER2-low and HER2-ultralow breast cancer using current immunohistochemistry diagnostic kits.

The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world.

Declines in the death rate for breast cancer have furthered overall progress in cancer mortality.

David Rimm, MD, PhD, from Yale Cancer Center discussed new study results at SABCS which identified quantitative multiplex immunofluorescence assay as an optimal way to detect TROP2 and HER2 expression among patients with breast cancer.

A novel selective biomarker (Troplex) may help select which antibody-drug conjugate therapy could be most effective in patients with metastatic breast cancer, according to findings presented at the 2023 San Antonio Breast Cancer Symposium.